IceCure Medical’s ProSense® Shows Promising Trial Results

Icecure Medical (ICCM) has released an update.

IceCure Medical’s ProSense® Cryoablation system has demonstrated a 96.3% recurrence-free rate in early-stage, low-risk breast cancer, offering a minimally invasive alternative to surgery with high patient and physician satisfaction regarding cosmetic outcomes. The results of the ICE3 trial, published in the Annals of Surgical Oncology, indicate the procedure’s safety and effectiveness, paving the way for potential FDA marketing authorization.

For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.